Skip to main content

Compare Stocks

Date Range: 

 Albireo PharmaKadmonXenon PharmaceuticalsChinook TherapeuticsKalVista Pharmaceuticals
SymbolNASDAQ:ALBONASDAQ:KDMNNASDAQ:XENENASDAQ:KDNYNASDAQ:KALV
Price Information
Current Price$29.85$3.58$17.56$15.28$25.04
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.51.81.61.41.6
Analysis Score3.53.53.53.53.5
Community Score2.53.22.72.83.0
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.70.01.7
Earnings & Valuation Score0.00.60.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$72.00$12.75$25.25$30.33$50.17
% Upside from Price Target141.21% upside256.15% upside43.79% upside98.52% upside100.35% upside
Trade Information
Market Cap$570.48 million$618.54 million$734.47 million$668.80 million$617.67 million
Beta1.621.681.20.262.13
Average Volume174,2043,358,453178,255181,889842,172
Sales & Book Value
Annual Revenue$9.64 million$5.09 million$6.83 million$17.26 million$12.69 million
Price / Sales59.44120.85105.3237.5247.96
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$7.34 per share$0.95 per share$2.99 per share$4.07 per share$4.69 per share
Price / Book4.073.775.873.755.34
Profitability
Net Income$-62,720,000.00$-61,370,000.00$-41,600,000.00$-82,370,000.00$-29,120,000.00
EPS($5.04)($0.74)($1.54)($5.15)($1.64)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-751.53%-768.36%-102.25%-215.80%-229.45%
Return on Equity (ROE)-71.22%-85.07%-21.76%-112.72%-47.45%
Return on Assets (ROA)-42.91%-46.46%-16.08%-21.36%-41.84%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.04%0.02%N/AN/AN/A
Current Ratio13.52%5.76%9.83%11.27%7.56%
Quick Ratio13.51%5.76%9.83%11.27%7.56%
Ownership Information
Institutional Ownership Percentage85.65%94.78%79.90%N/A90.19%
Insider Ownership Percentage5.00%2.95%8.35%5.90%18.00%
Miscellaneous
Employees9012712310556
Shares Outstanding19.20 million171.82 million40.96 million42.38 million24.31 million
Next Earnings Date8/5/2021 (Estimated)8/5/2021 (Estimated)8/5/2021 (Estimated)5/17/2021 (Estimated)7/7/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableNot Optionable
SourceHeadline
Hereditary Angioedema Therapeutics Market - Forecast to 2026Hereditary Angioedema Therapeutics Market - Forecast to 2026
openpr.com - May 11 at 9:01 AM
KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema WorkshopKalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop
finance.yahoo.com - May 10 at 8:52 AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Christopher Yea Sells 5,000 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Christopher Yea Sells 5,000 Shares
americanbankingnews.com - May 6 at 8:56 PM
KalVista Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:KALV)KalVista Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:KALV)
americanbankingnews.com - May 5 at 7:40 AM
KalVista bulks up executive team with CMO addition as angioedema franchise grinds to launchKalVista bulks up executive team with CMO addition as angioedema franchise grinds to launch
fiercebiotech.com - May 3 at 11:08 AM
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical OfficerKalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer
finance.yahoo.com - May 3 at 11:08 AM
Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) VP Sells 10,014 Shares of StockInsider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) VP Sells 10,014 Shares of Stock
americanbankingnews.com - May 3 at 4:52 AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) SVP Sells $284,128.43 in StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) SVP Sells $284,128.43 in Stock
americanbankingnews.com - April 30 at 4:50 PM
Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) SVP Sells 88,030 Shares of StockInsider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) SVP Sells 88,030 Shares of Stock
americanbankingnews.com - April 30 at 1:22 PM
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up to $24.47KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up to $24.47
americanbankingnews.com - April 27 at 11:18 AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by AnalystsKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by Analysts
americanbankingnews.com - April 25 at 6:24 AM
KalVista Pharmaceuticals (NASDAQ:KALV) Trading Down 4.3%KalVista Pharmaceuticals (NASDAQ:KALV) Trading Down 4.3%
americanbankingnews.com - April 23 at 3:42 PM
What You Need To Know About KalVista Pharmaceuticals, Inc.s (NASDAQ:KALV) Investor CompositionWhat You Need To Know About KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) Investor Composition
nasdaq.com - April 22 at 7:25 PM
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 7.7% Higher KalVista Pharmaceuticals (NASDAQ:KALV) Trading 7.7% Higher
americanbankingnews.com - April 22 at 1:58 PM
KalVista’s Hereditary Angioedema Trial On HoldKalVista’s Hereditary Angioedema Trial On Hold
pharmalive.com - April 21 at 4:05 AM
Regulatory progress for two biotechs stalls as FDA requests more informationRegulatory progress for two biotechs stalls as FDA requests more information
medcitynews.com - April 20 at 5:21 PM
KalVista hit with a clinical hold on 2nd asset as fortunes ebb and flowKalVista hit with a clinical hold on 2nd asset as fortunes ebb and flow
fiercebiotech.com - April 20 at 12:21 PM
KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824
finance.yahoo.com - April 20 at 12:21 PM
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down to $23.12KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down to $23.12
americanbankingnews.com - April 20 at 11:40 AM
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
finance.yahoo.com - April 20 at 7:21 AM
KalVista Pharmaceuticals IncKalVista Pharmaceuticals Inc
bloomberg.com - April 18 at 10:30 PM
Kalvista Pharmaceuticals Inc (KALV)Kalvista Pharmaceuticals Inc (KALV)
investing.com - April 18 at 5:28 PM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) -2.98% decline turns away investor interest in company’s stockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) -2.98% decline turns away investor interest in company’s stock
stocksregister.com - April 18 at 7:24 AM
Short Interest in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Increases By 51.8%Short Interest in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Increases By 51.8%
americanbankingnews.com - April 17 at 10:30 AM
What Is The Ownership Structure Like For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)?What Is The Ownership Structure Like For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)?
finance.yahoo.com - March 29 at 9:05 AM
DateCompanyBrokerageAction
3/26/2021Albireo PharmaJefferies Financial GroupBoost Price Target
3/8/2021Albireo PharmaPiper SandlerBoost Price Target
3/1/2021Albireo PharmaRobert W. BairdReiterated Rating
12/18/2020Albireo PharmaHC WainwrightBoost Price Target
11/19/2020Albireo PharmaWedbushReiterated Rating
9/10/2020Albireo PharmaCowenBoost Price Target
9/8/2020Albireo PharmaNeedham & Company LLCBoost Price Target
8/10/2020Albireo PharmaWilliam BlairReiterated Rating
3/11/2021KadmonRaymond JamesBoost Price Target
11/11/2020KadmonMizuhoInitiated Coverage
10/9/2020KadmonCantor FitzgeraldReiterated Rating
9/22/2020KadmonOppenheimerReiterated Rating
1/10/2020KadmonNomura SecuritiesInitiated Coverage
2/26/2019KadmonCitigroupUpgrade
10/17/2018KadmonWBB SecuritiesUpgrade
3/8/2021Xenon PharmaceuticalsSVB LeerinkBoost Price Target
8/13/2020Xenon PharmaceuticalsBloom BurtonReiterated Rating
9/20/2019Xenon PharmaceuticalsGuggenheimInitiated Coverage
3/29/2019Xenon PharmaceuticalsStifel NicolausReiterated Rating
11/2/2020Chinook TherapeuticsEvercore ISIInitiated Coverage
2/25/2021KalVista PharmaceuticalsRoth CapitalBoost Price Target
(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.